Helm E B, Dillmann W, Stille W
MMW Munch Med Wochenschr. 1978 Mar 3;120(9):293-6.
As a result of our experience in 266 persons vaccinated with HDC vaccine we consider this type of vaccine to be a great advance. In spite of our very positive judgement we are of the opinion that vaccination should not be done without adequate indication. This type of vaccine contains certain imponderables which argue against widespread vaccination. At any rate, complications occurred in one of our patients vaccinated with HDC vaccine Mérieux. Nevertheless we consider vaccination before exposure of persons who are genuinely at risk, such as veterinarians, laboratory staff in rabies laboratories and possibly also hunters and agriculturalists in infected areas to be acceptable.
由于我们对266名接种人二倍体细胞狂犬病疫苗（HDC疫苗）的人员的经验，我们认为这种类型的疫苗是一个巨大的进步。尽管我们的评价非常积极，但我们认为没有充分指征不应进行疫苗接种。这种类型的疫苗包含某些难以估量的因素，这反对广泛接种。无论如何，我们一名接种了巴斯德梅里厄公司生产的人二倍体细胞狂犬病疫苗的患者出现了并发症。然而，我们认为对真正有风险的人员，如兽医、狂犬病实验室的实验室工作人员以及可能还有感染地区的猎人及农业工作者，在暴露前进行疫苗接种是可以接受的。
